Silence Therapeutics (SLN) investor relations material

Strategic vision and technology

• Focus on silencing disease-causing genes using proprietary siRNA technology for precision medicines.

• siRNA therapies are designed to be natural, precise, durable yet reversible, and broadly applicable to many genes.

• Expertise spans drug discovery, design, and clinical development with operations in the US, UK, and Germany.

• Continuous innovation in siRNA and ligand design enhances stability, activity, and targeted delivery, especially to the liver.

Pipeline and clinical progress

• Lead asset divesiran targets polycythemia vera (PV), showing robust efficacy, durable response, and favorable safety in Phase 1.

• Phase 2 SANRECO study for divesiran in PV is fully enrolled, with topline results expected in Q3 2026.

• SLN312 (ANGPTL3) for dyslipidemia demonstrated strong Phase 1 results; exclusive rights to revert after Phase 1.

• SLN365 (GPR146) and SLN098 (INHBE) are advancing preclinically for HoFH and obesity, respectively, with IND filings targeted for 2027.

Clinical data highlights

• Divesiran reduced phlebotomy needs, controlled hematocrit, and improved iron stores in PV patients, with effects lasting nearly a year post-treatment.

• Divesiran showed no dose-limiting toxicities or serious adverse events in Phase 1.

• SLN312 achieved robust, dose-dependent reductions in ANGPTL3 and lipids, supporting infrequent dosing.

• SLN365 and SLN098 demonstrated significant gene knockdown and metabolic improvements in preclinical models.